Tvardi Therapeutics (TVRD) versus Its Competitors Critical Analysis

Tvardi Therapeutics (NASDAQ:TVRD – Get Free Report) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Tvardi Therapeutics to similar companies based on the strength of its valuation, institutional ownership, earnings, dividends, profitability, analyst recommendations and risk.

Institutional and Insider Ownership

44.7% of Tvardi Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 7.4% of Tvardi Therapeutics shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Volatility and Risk

Tvardi Therapeutics has a beta of 0.37, suggesting that its share price is 63% less volatile than the S&P 500. Comparatively, Tvardi Therapeutics’ competitors have a beta of -3.77, suggesting that their average share price is 477% less volatile than the S&P 500.

Profitability

This table compares Tvardi Therapeutics and its competitors’ net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Tvardi Therapeutics and its competitors gross revenue, earnings per share and valuation.

Tvardi Therapeutics’ competitors have higher revenue and earnings than Tvardi Therapeutics. Tvardi Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a summary of recent ratings and target prices for Tvardi Therapeutics and its competitors, as reported by MarketBeat.com.

Tvardi Therapeutics presently has a consensus target price of $9.40, indicating a potential upside of 608.90%. As a group, “Pharmaceuticals” companies have a potential upside of 24.23%. Given Tvardi Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Tvardi Therapeutics is more favorable than its competitors.

Summary

Tvardi Therapeutics beats its competitors on 8 of the 13 factors compared.

About Tvardi Therapeutics

(Get Free Report)

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.